Dimethyl fumarate: a new oral treatment option for multiple sclerosis


  • Sarjana S. Atal Senior Lecturer, Department of Pharmacology, Modern Dental College and Research Centre, Indore, Madhya Pradesh, India
  • Shubham S. Atal Assistant Professor, Department of Pharmacology, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh, India


Fumaric acid, Tecfidera, Multiple sclerosis, Immunomodulation, Neuroprotective effects


Multiple Sclerosis (MS) is a slowly progressive, immunologically mediated disease of the CNS. The recent years have witnessed great efforts in establishing new therapeutic options for multiple sclerosis. There is a clear need for more effective, safe and at the same time orally available treatment options. Here we review the recently approved drug Dimethyl fumarate (DMF, Tecfidera®) as a new therapeutic option for MS and its role in context to the existing oral treatment options for MS. Dimethyl fumarate is the methyl ester of fumaric acid and has been claimed to possess immunomodulatory properties and is already in clinical use as Fumaderm for severe systemic psoriasis. In addition, Dimethyl fumarate was also shown to act on the blood-brain barrier and exert neuroprotective properties via activation of anti-oxidative pathways and displayed beneficial effects in experimental autoimmune encephalomyelitis (EAE), a model mimicking many aspects of MS. Based on two global phase III studies. Dimethyl fumarate has been clinically proven to significantly reduce important measures of disease activity, including relapses and development of brain lesions, as well as to slow disability progression over time, while demonstrating a favourable safety and tolerability profile.


Annapurna A, Krishna Kumar V, Murali Mohan RaoP, SomeswaraRao K and Rajasekhar J. Multiple Sclerosis: The disease and its treatment. Indian Journal of Pharmacology 2002; 34:3-15.

Olek M. Epidemiology and clinical features of multiple sclerosis in adults. 2013. Available at http://www.uptodate.com/contents/epidemiology-and-clinical-features-of-multiple-sclerosis-in-adults. Accessed 10 June 2013.

Pugliatti M, Rosati.G, Carton H, Riise T, Druvolic J, Vecsei L et al. The epidemiology of multiple sclerosis in Europe. European Journal of Neurology 2006, 13:700-22.

Neurological disorders: A public health approach. In: Neurological Disorders: Public Health Challenges. World Health Organization. Geneva, Switzerland: WHO Press; 2007. Available at http://www.who.int/mental_health/neurology/neurodiso/en/index.html. Accessed 2 August 2013.

Lublin F and Reingold S. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology.1996; 46:907–911.

Marriott J and O’Connor P. Emerging therapies in Relapsing-Remitting Multiple sclerosis. Rev Recent Clin Trials 2010; 5:179-88.

Loma I and Heyman R. Multiple sclerosis: Pathogenesis and treatment. Current Neuropharmacology 2011; 9:409-416.

FDA Approves oral Teriflunomide – Brand name Aubagio – as Disease Modifying therapy for Relapsing MS, 2012. Available at http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6864. Accessed 4 March 2013.

Update FDA approves Fingolimod – Brand Name Gilenya – First oral Disease Modifying Therapy for Relapsing MS- Now available by prescription, 2010. Available at http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=3871. Accessed 4 March 2013.

Pandit L and Murthy J. Treatment of multiple sclerosis. Ann Indian Acad Neurol 2011; 14(l1):65–69.

AntonieR ,Kristian R and Almut B. Use of fumaric acid esters in psoriasis.Indian Journal of Dermatology, Venereology and Leprology 2007; 73(2): 133-137.

Mrowietz U and Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends in Molecular Medicine 2005; 11(1):43-48.

Biogen Idec’s TECFIDERATM (Dimethyl fumarate) approved in US as a First-line oral treatment for Multiple sclerosis. Biogen Idec Press Release.2013 Mar 27. Available at http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1801165. Accessed 5 March 2013.

Fransson M, Liljienfeldt L, Fagius J, Totterman T and Loskog A. The T-cell pool is anergized in patients with multiple sclerosis in remission. Immunology 2009; 126(1):92-101.

Hafler D. Multiple sclerosis. J Clin Invest. 2004; 113(6): 788–794.

Inglesea M. Multiple sclerosis: New Insights and Trends. AJNR May 2006, 27: 954-957.

Link H. The cytokine storm in multiple sclerosis. Multiple Sclerosis 1998, 4:12-15.

Steinman L. Multiple Sclerosis: a two-stage disease. Nature Immunology 2001, 2(9):762-64.

Schilling S, Goelz S, Linker R, Luehder F and Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clinical and Experimental Immunology 2006, 145:101-7.

De Jong R, Bezemer A, Zomerdijk T, Van de Pouw-Kraan T, Oteenhoff T and Nibbering P. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent mono methyl fumarate. Eur J Immunol 1996, 26(9):2067-74.

Wilms H, Sievers J , Rickert U , Rostami-Yazdi M , Mrowietz U and Lucius R.Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation. Journal of Neuroinflammation 2010, 7:30:1-8.

Scannevin R, Chollate S, Jung M , Shackett M, Patel H, Bista P, et al. Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway . JPET 2012, 341:274–284.

Linker R, Lee D, Ryan S, Van Dam A, Conrad R , Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134(3):678-92.

Albrecht P , Bouchachia I, Goebels N, Henke N, Harald H, Issberner A et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. Journal of Neuroinflammation 2012,9:163:1-10.

Zhao J, Moore A, Redell J and Dash P. Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury. J Neurosci 2007; 27(38):10240-8.

Loewe R, Pilinger M, Martin R, Mrowietz U, Groger M , Holnthoner W et al . Dimethylfumarate inhibits Tumor-Necrosis-Factor-Induced CD62E Expression in an NF-KB-Dependent manner. The Journal of Investigative Dermatology 2001, 117(6):1363-68.

Werdenberg D , Joshi R, Wolffram S, Merkle H and Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos 2003, 24(6):259-73.

Khiabani D, Linker R, Gold R and Stangel M. Fumaric acid and its esters: An Emerging treatment for Multiple Sclerosis. Curr Neuro pharmacol 2009, 7(1):60-64.

Lee D, Linker R and Gold R. Spotlight on Fumarates. The International MS Journal 2008, 15:12-18.

Mrowietz U, Christophers E and Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric acid ester Consensus Conference. Br J Dermatol 1999, 141(3):424-9.

Phillips J and Fox R. BG-12 in Multiple Sclerosis. Semin Neurol 2013; 33:56–65.

Phillips J, Fox R, Miller D, Kita M, Hutchinson M, Havrdova E. et al. Safety and Tolerability of BG-12 in patients with Relapsing – Remitting Multiple Sclerosis (RRMS): Analyses from the CONFIRM study (S41.005).

Litjens N, Burggraaf J, Van Strijen E, Gulpen C, Mattie H , Schoemaker R et al. Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol 2004, 58(4):429-32.

Gold R, Phillips J, Havrdova E, Bar-Or A, Kappos L, Yuan H et al. BG-12(Dimethyl Fumarate) and pregnancy: Preclinical and clinical data from the clinical development program. Neurology 2013.

Sobieraj D and Coleman C. Dimethyl fumarate: A fumaric acid ester under investigation for treatment of relapsing-remitting multiple sclerosis. Formulary 2012, 47:386-91.

ClinicalTrials.gov/. Long-term safety and efficacy study of oral BG00012 monotherapy in relapsing-remitting multiple sclerosis 2012.NCT00835770. Available at http://www.clinicaltrials.gov/ct2/show/NCT00835770?term=BG-12&rank=5/. Accessed 5 March 2013.

Gold R, Arnold D, Kappos L, et al. Baseline characteristics of patients in the DEFINE trial: A randomized, multicenter, double-blind, placebo-controlled, randomized, phase 3 study of BG-12 in relapsing-remitting multiple sclerosis. Neurology 2010; 74(9 Suppl 2):546–47.

Biogen Idec press release. Oral BG-12 (dimethyl fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression in DEFINE phase 3 clinical trial. October 21, 2011.Available at: http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqID=1619878/. Accessed 5 April 2013.

Giovannoni G, Gold R, Kappos L, et al. BG-12 increases the proportion of patients free of clinical and radiologic disease activity in relapsing-remitting multiple sclerosis: Findings from the DEFINE study (PD5.005). Available at http://www.neurology.org/cgi/content/meeting_abstract/78/1_MeetingAbstracts/PD5.005/. Accessed 3 September 2013.

Fox R, Miller D, Phillips T, et al. Baseline characteristics of patients enrolled in a randomized, multicenter, placebo-controlled and active comparator trial evaluating efficacy and safety of BG-12 in relapsing-remitting multiple sclerosis: The CONFIRM trial. Neurology 2010; 74(9 Suppl 2):A549.




How to Cite

Atal, S. S., & Atal, S. S. (2017). Dimethyl fumarate: a new oral treatment option for multiple sclerosis. International Journal of Basic & Clinical Pharmacology, 2(6), 849–856. Retrieved from https://www.ijbcp.com/index.php/ijbcp/article/view/1384



New Drug Update